KROSKeros Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- $244M
- 6775% YoY
- Operating margin
- 27.7%
- 100% YoY
- EBITDA
- $69M
- 133% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 2 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear124% of net incomeCash flow under 80% of net income
- Dilutive SBCFired12% of revenueOver 10% of revenue
- Payouts exceed cash flowFired349% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $20M | $0 | $151K | $4M | $244M | 6775% |
| Operating income | −$56M | −$115M | −$170M | −$211M | $68M | 132% |
| Net income | −$59M | −$105M | −$153M | −$187M | $87M | 146% |
| Operating cash flow | −$62M | −$70M | −$125M | −$161M | $108M | 167% |
| Capex | $1M | $1M | $2M | $2M | $2M | 20% |
| Stock-based comp | $12M | $19M | $29M | $35M | $29M | 18% |
| Buybacks | — | — | — | $0 | $375M |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $3M | $4M | 29 | — |
| FY2024 | $6M | $3M | 22 | — |
| FY2023 | $9M | $3M | 56 | — |